/EW
Edwards Lifesciences Corporation
EW • NYSEEW • NYSE • Healthcare
$81.64-2.68%-2.25
$81.64-2.68%(-2.25)Healthcare
GoAI Score
Sign in to unlock
Valuation
50Fair Value
Sentiment
89Bullish
Risk
83Low Risk
Momentum
50Neutral
Institutional-Grade Intelligence
🏆PRO
Actionable Intelligence
AI-driven stance, execution logic & risk thresholds
Catalyst Roadmap
Event timeline with expected impact & market context
Deep Insights
Fact-checked analysis & score logic breakdown
Financial Statements
Margin Trends
Gross
78.1%▼1.3pp
Revenue after COGS
Operating
27.0%▲1.6pp
After operating expenses
Net
17.7%▼59.1pp
Bottom-line profitability
Gross Margin
Operating Margin
Net Margin
Valuation Snapshot
P/E Ratio
46.4
Price vs earnings
EV/EBITDA
33.3
Enterprise value
FCF Yield
2.7%
Cash generation
Earnings Yield
2.2%
Inverse of P/E
Capital Efficiency
10
GoAI Quality ScoreFair
ROEReturn on Equity
10.4%Fair
ROAReturn on Assets
7.8%Strong
ROICReturn on Invested Capital
11.4%Strong
Financial Health
Current RatioHealthy
3.72
Short-term solvency (>1.5)
Net Debt / EBITDANet Cash
-1.56x
Debt repayment capacity (<3x)
Income QualityStrong
1.49
Cash backs earnings (>1)
Revenue & Profitability
Revenue
Net Income
Net Loss
Income Statement
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $6.07B | $5.44B | $5.01B | $5.38B | $5.23B |
| Gross Profit | $4.74B | $4.32B | $3.97B | $4.22B | $4.01B |
| Gross Margin | 78.1% | 79.5% | 79.3% | 78.3% | 76.6% |
| Operating Income | $1.64B | $1.38B | $1.43B | $1.70B | $1.61B |
| Net Income | $1.07B | $4.17B | $1.40B | $1.52B | $1.50B |
| Net Margin | 17.7% | 76.7% | 28.0% | 28.3% | 28.7% |
| EPS | $1.84 | $6.98 | $2.31 | $2.46 | $2.41 |
Average Price Target
$96.38▲ 18.1% Upside
Past 12 Months
12 Month Forecast
Based on 50 Wall Street analysts offering 12 month price targets for Edwards Lifesciences Corporation, the average price target is $96.38, with a high forecast of $110.00 and a low forecast of $87.00. The average price target represents a 18.1% increase from the current price of $81.64.
Highest
$110.00
Average
$96.38
Lowest
$87.00
Rating Distribution
Strong Buy
0
0%
Buy
32
67%
Hold
16
33%
Sell
0
0%
Strong Sell
0
0%
Recent Analyst Ratings
FirmActionRatingDate
Goldman Sachs● Maintain
Buy
2026-02-11Piper Sandler● Maintain
Overweight
2026-02-11BTIG● Maintain
Buy
2026-02-11Wells Fargo● Maintain
Overweight
2026-02-11Truist Securities● Maintain
Hold
2026-02-11Stifel● Maintain
Buy
2026-01-20Piper Sandler● Maintain
Overweight
2026-01-20Barclays● Maintain
Overweight
2026-01-12UBS● Maintain
Neutral
2026-01-12TD Cowen▲ Upgrade
Hold→Buy
2026-01-09Earnings History & Surprises
BEAT RATE
67%
Last 18 quarters
AVG SURPRISE
+2.1%
EPS vs Estimate
BEATS / MISSES
12/4
2 met exactly
LATEST EPS
$0.58
Q1 '26
QUARTERLY EPS TREND
Estimated
Beat
Miss
QUARTERLY DETAIL
Q1 '26
-6.3%
$0.58 vs $0.62
Q4 '25
+12.4%
$0.67 vs $0.60
Q3 '25
+7.4%
$0.67 vs $0.62
Q2 '25
+7.4%
$0.64 vs $0.60
Q1 '25
+7.1%
$0.59 vs $0.55
Q4 '24
+0.8%
$0.67 vs $0.67
Q3 '24
+1.4%
$0.70 vs $0.69
Q2 '24
+3.1%
$0.66 vs $0.64
Q1 '24
$0.64 vs $0.64
Q4 '23
$0.59 vs $0.59
Q3 '23
+1.5%
$0.66 vs $0.65
Q2 '23
+1.6%
$0.62 vs $0.61
No investor questions available.
Latest News
No news available